The post-test for this issue is available for one year after the publication date to subscribers. By successfully completing the test you will be awarded a certificate for 2 CME credits.
Read More
Ramelteon (Rozerem) is one of the safer sleep medications, but how well does its efficacy stack up against other hypnotics? The answer surprised us.
Read More
Psychotherapy can work as well as medication, but can it also have side effects? Michael Linden believes it can. He launched some of the key studies that brought light to this under-appreciated phenomenon, and in this interview he shows us how to recognize and avoid them.
Read More
Every minute counts in the 90833 “brief therapy with medication” visit, and Donna Sudak shows us how to customize CBT with pharmacotherapy for depression, bipolar, anxiety disorders, and schizophrenia.
Read More
After digging through 3 decades of research, we can tell you this: There is no such thing as “the best” SSRI. But there are some important differences between them, and this article will show you how to find the right one for your patient.
Read More
Two recent studies add to the mounting evidence that environmental toxins deserve a place in the bio-psycho-social-spiritual model. The first study correlated ADHD symptoms with exposure to endocrine-disrupting chemicals found in plastics, pesticides, and processed food. The second study was a meta-analysis of ultra-processed food consumption from 23 cross-sectional and prospective cohort studies.
Read More
Antihypertensives are among the world’s most widely prescribed drugs, but many of them impact pathways associated with depression. Beta blockers have long been believed to cause depression, but most of these studies were carried out decades ago and their findings have been inconsistent.
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
